Publications by authors named "Samuel Denmeade"

Claim this Profile
A
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer.
Rajendra Kumar, Sheila Jonnatan, David E Sanin, Varsha Vakkala, Anoushka Kadam, Samuel R Denmeade

Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
David R Wise, Russell K Pachynski, Samuel R Denmeade, Rahul R Aggarwal, Jiehui Deng

Prostate Cancer Prostatic Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.
Mayuko Kanayama, Hua-Ling Tsai, Hao Wang, Emmanuel S Antonarakis, Samuel R Denmeade

Prostate Cancer Prostatic Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
Jarey H Wang, Alexander D Sherry, Soha Bazyar, Philip Sutera, Noura Radwan, Samuel Denmeade

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study.
Ezra G Baraban, Evangelia Vlachou, Sunil Patel, Max Kates, Burles Johnson, Samuel R Denmeade

Prostate· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes.
Yasaman Iranmanesh, Noha Omar, Arya Rasouli, Alex Baras, Sergiu Pasca, Samuel R Denmeade

Oncologist· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor.
Rajendra Kumar, Janet Mendonca, Abhishek Shetty, Yuhan Yang, Olutosin Owoyemi, Samuel R Denmeade

FASEB J· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer.
Rajendra Kumar, Sheila Jonnatan, David E Sanin, Varsha Vakkala, Anoushka Kadam, Samuel R Denmeade

medRxiv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial Experience with [Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
Andrei Gafita, Andrew Voter, Somya Shesadri, Avery Spitz, Catherine H Marshall, Samuel R Denmeade

J Nucl Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, Lia Oliveira, Hao Wang, Samuel R Denmeade

JAMA Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.
Channing J Paller, Marianna L Zahurak, Adel Mandl, Nicole A Metri, Aliya Lalji, Samuel R Denmeade

Cancer Res Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
Sumer Jasmine, Adel Mandl, Timothy E G Krueger, Susan L Dalrymple, Lizamma Antony, Samuel R Denmeade

Prostate· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
Catherine H Marshall, Lukasz P Gondek, Violet Daniels, Changxue Lu, Sergiu Pasca, Samuel R Denmeade

Prostate· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer.
Joakin O Mori, Isra Elhussin, W Nathaniel Brennen, Mindy K Graham, Tamara L Lotan, Samuel R Denmeade

Nat Rev Urol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.
Samuel R Denmeade

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor.
Rajendra Kumar, Janet Mendonca, Abhishek Shetty, Yuhan Yang, Olutosin Owoyemi, Samuel Denmeade

bioRxiv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A Sena, Hao Wang, Samuel R Denmeade

Nat Commun· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
John T Isaacs, Susan L Dalrymple, Lizamma Antony, David Marc Rosen, Ilsa M Coleman, Samuel R Denmeade

Prostate· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer.
Laura A Sena, Hao Wang, Samuel R Denmeade

Prostate· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver Fibrosis Scores and Prostate Cancer Risk and Mortality in the Atherosclerosis Risk in Communities Study.
Anqi Wang, Mariana Lazo, Jiayun Lu, David J Couper, Anna E Prizment, Samuel R Denmeade

Cancer Prev Res (Phila)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Samuel R Denmeade, Laura A Sena, Hao Wang, Emmanuel S Antonarakis, Mark C Markowski

Oncologist· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.
Rajendra Kumar, Laura A Sena, Samuel R Denmeade, Sushant Kachhap

Nat Rev Urol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
Eugene Shenderov, Angelo M De Marzo, Tamara L Lotan, Hao Wang, Sin Chan, Samuel R Denmeade

Nat Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer.
Laura A Sena, Tingchang Wang, Hao Wang, Mark C Markowski, Emmanuel S Antonarakis, Samuel R Denmeade

Eur J Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, Daniel Y Song, Arthur Y Hung, Samuel Denmeade

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis